Clinical trial · Observational
Influence of Hormone Treatment in Radiation Therapy for Bladder Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Bladder cancer is often treated with cystectomy or radiation therapy. Following radiation therapy patients will often have severe side effects from the treatment. Studies have suggested that simultanously treatment with androgen deprivation therapy during radiation therapy may be able to proctect stemcells in the bladder, thus improving tissue recovering post-radiation, which would result in improved bladder compliance following the treatment and ultimately result in fewer side effects and overall improved patient quality of life.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Cancer | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
| Quality of Life | — | UNRESOLVED | — |
| Radiation Therapy Complication | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Degarelix | Drug | Degarelix | ALIAS |
Design
Arms and outcomes
Arms (2)
- label
- Degarelix
- description
- Patients undergoing radiation therapy for bladder cancer while also being treated with Degarelix (androgen deprivation therapy)
- interventionNames
- Drug: Degarelix
- label
- Control
- description
- Patients undergoing radiation therapy for bladder cancer with or without simultanous treatment with androgen deprivation therapy (not Degarelix)
Primary outcomes (1)
- measure
- Bladder fibrosis
- timeFrame
- 3 months after radiation
- description
- Fibrosis of the bladder determined by bladder biopsy estimated by number of fibrotic fibers on IHC staining
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * T2-T4 bladder cancer * radiation therapy * able to fill out questionnaires * signed informed consent Exclusion Criteria: * KAD prior to TUR-B * dementia or other cognitive impairment * metastatic disease
References
Publications (0)
Data not yet available